John Lechleiter News
-
Eli Lilly & Co. Chief Executive Officer John Lechleiter underwent a scheduled surgery yesterday for a heart defect and the repair to the aorta is functioning as intended, the drugmaker said.
-
Eli Lilly & Co. said John Lechleiter, the drugmaker’s chairman and chief executive officer, will undergo surgery for a dilated aorta, an asymptomatic condition from which he is expected to recover.
-
Eli Lilly & Co. said first-quarter profit exceeded analysts’ estimates as the company cut jobs and had a lower tax rate from the reinstatement of a research and development credit.
-
Drugmaker Eli Lilly & Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, Chief Executive Officer John Lechleiter said.
-
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. Chief Executive Officer John Lechleiter plans to tell a technology conference today.
-
Eli Lilly & Co. Chief Executive Officer John Lechleiter said during a panel discussion in Washington that U.S. lawmakers should renew the research-and- development tax credit to make it easier for companies to compete globally. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News in Washington, centered on ways to spur innovation.
-
Eli Lilly & Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting to overcome the revenue loss, Chief Executive Officer John Lechleiter said.
-
In trying to get sophisticated medicines to its neediest citizens, India is increasingly pitting its generic-pharmaceutical industry against international drugmakers, threatening their growth in emerging markets.
-
Eli Lilly & Co. Chief Executive Officer John Lechleiter said rising sales of the antidepressant Cymbalta and animal drugs stemmed losses from generic competition, helping the company’s earnings beat estimates.
-
China takes eight years longer on average to approve drugs than other major countries and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly & Co. Chief Executive Officer John Lechleiter said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page